伊立替康联合顺铂治疗复发性卵巢癌的效果分析

目的 观察伊立替康联合顺铂治疗复发性卵巢癌的临床疗效.方法 将我院从2008年8月至2010年10月我院收治的例136例一线治疗复发的卵巢癌病患随机平均分为实验组68例,应用伊立替康联合顺铂治疗,对照组68例单用伊立替康治疗,分别均进行9周以上化疗.结果 实验组治疗有效率(CR+PR)为44.1％,CP7例,PR23例,SD28例,PD10例；对照组治疗有效率为42.6％,CP6例,PR23例,SD29例,PD9例.两组数据间差异无显著性(P＞0.05).两组均无过敏反应和极少肝肾功能损伤发生,主要表现为骨髓抑制和胃肠道反应,少数病患表现为外周神经毒性和静脉炎,在骨髓抑制和恶心呕吐上差异有显著性(P＜0.05),实验组优于对照组.结论 伊立替康联合顺铂治疗复发性卵巢癌能取得良好效果,且具有较小的骨髓抑制和呕吐反应.

Analysis on the curative effects of irinotecan combined with cisplatin in recurrent ovarian cancer treatment

Objective To analyze the therapeutic effect of irinotecan combined with cisplatin in recurrent ovarian cancer treatment. Methods 136 patients with recurrent ovarian cancer received in our hos- pital from Aug 2006 to Oct 2011,were randomly divided into two groups. Group experiment （GE） consisted of 68 patients who reiceived irinotecan combined with cisplatin and group controlled （GC） with 41 patients received irinotecan alone. The treatment lasted for 9 weeks.Results In GE and GC groups, the effective treatment rate （CR＋PR） was 44.1% and 42.6% （,~〉0.05） respectively. There was no particular adverse effect, such as anaphylaxis, hepatic or kidney injury, and the most common ones were myelosuppression and gastrointestinal response, in addition a fewer patients showed neuropathy and phlebitis in each group; the rate of myelosuppression and gastrointestinal response showed significant difference between each other, and the GE was better than the GC （P 〈0.05）.Conclusien The treatment of irinotecan combined with cisplatin in recurrent ovarian cancer treatment can achieve better therapeutic effect with lower myelosuppression and gastrointestinal response,